TG Therapeutics(TGTX)
NEW YORK, NYBiotechnology
Focus: TG Therapeutics is a publicly traded biotechnology company headquartered in New York specializing in biologics for oncology, neurology, and immunology. The company generated $234M in revenue in FY 2025, demonstrating rapid commercial traction following recent product approvals.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About TG Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow TG Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from TG Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
7 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$234M
Key Products
Growing
Peak8.6yr
Sole approved product driving FY 2025 revenue of $234M; patent protection extends to 2035 providing long-term commercial runway.
Help build intelligence for TG Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.